Quick Answer
Arbutus Biopharma Corp reported Operating Income of -$38.16 million for fiscal year 2025.
Arbutus Biopharma Corp Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$38.16M | +50.0% |
| 2024 | -$76.32M | +2.3% |
| 2023 | -$78.10M | -19.3% |
| 2022 | -$65.46M | +11.0% |
| 2021 | -$73.52M | -27.2% |
| 2020 | -$57.81M | +59.8% |
| 2019 | -$143.90M | -60.3% |
| 2018 | -$89.78M | +19.1% |
| 2017 | -$110.93M | +77.4% |
| 2016 | -$491.64M | -373.1% |
| 2015 | -$103.92M | -210.8% |
| 2014 | -$33.43M | -175.1% |
| 2013 | -$12.15M | +6.1% |
| 2012 | -$12.95M | -21.1% |
| 2011 | -$10.69M | +14.6% |
| 2010 | -$12.52M | -47.6% |
| 2009 | -$8.48M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$8.66M | +59.6% | -681.9% |
| June 30, 2025 | $1.49M | +106.9% | +105.8% |
| March 31, 2025 | -$25.70M | -32.7% | -19.9% |
| September 30, 2024 | -$21.44M | +0.5% | +0.7% |
| June 30, 2024 | -$21.58M | -17.4% | -11.5% |
| March 31, 2024 | -$19.36M | -11.2% | +10.2% |
| September 30, 2023 | -$21.56M | -21.0% | -17.3% |
| June 30, 2023 | -$18.39M | -30.3% | -5.6% |
- Arbutus Biopharma Corp showed an increase of +50.0% in Operating Income compared to the prior fiscal year.
- Over the 2009–2025 period, Arbutus Biopharma Corp’s operating income has declined by 350.2% (from -$8.48 million to -$38.16 million).
- The most recent figure is from Arbutus Biopharma Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: